June 15, 2026 - Regulatory Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis – supports phase 3 design, regulatory interactions, and partnering
April 23, 2026 - Regulatory SynAct Pharma’s Nomination Committee ahead of the 2026 Annual General Meeting
March 2, 2026 - Regulatory SynAct Pharma has carried out a directed issue of new shares of approximately 51.9 MSEK
March 2, 2026 - Regulatory SynAct Pharma announces intention to carry out a directed issue of approximately 45 MSEK
January 9, 2026 - Regulatory The Board of Directors of SynAct Pharma AB (publ) has resolved on the repurchase of own shares
